CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000139:chemically induced* / Q000209:etiology; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000209:etiology; D013997:Time Factors; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine